证券日报网讯 12月9日晚间，富士莱发布公告称，公司于近日收到国家药品监督管理局签发的关于硫辛 酸片的《药品注册证书》。 （文章来源：证券日报） ...

智通财经APP讯，富士莱(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的 《药品注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。 ...

每经AI快讯，富士莱（SZ 301258，收盘价：32.62元）12月9日晚间发布公告称，苏州富士莱医药股份 有限公司于近日收到国家药品监督管理局签发的关于硫辛酸片的《药品注册证书》。产品名称为"硫辛 酸片"。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 王瀚黎） 2024年1至12月份，富士莱的营业收入构成为：医药占比99.19%，其他业务占比0.81%。 截至发稿，富士莱市值为30亿元。 ...

富士莱（301258）(301258.SZ)公告，公司近日收到国家药品监督管理局签发的关于硫辛酸片的《药品 注册证书》。硫辛酸片适应症为：用于糖尿病周围神经病变引起的感觉异常。 ...

人民财讯12月9日电，富士莱（301258）12月9日公告，公司于近日收到国家药品监督管理局签发的关于 硫辛酸片的《药品注册证书》。该药品用于糖尿病周围神经病变引起的感觉异常。 ...

Core Viewpoint - Garden Biologics (300401.SZ) announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has received the drug registration certificates for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" from the National Medical Products Administration [1] Group 1 - The "Alpha-Lipoic Acid Tablets" are primarily used for the treatment of diabetic peripheral neuropathy [1] - The "Bisoprolol Amlodipine Tablets" are mainly used for the treatment of hypertension and can be used alone or in combination with other antihypertensive medications [1]

Core Viewpoint - The company has received drug registration certificates for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets" from the National Medical Products Administration, which will enhance its product line and positively impact its development [1] Group 1 - The full subsidiary Zhejiang Huayuan Pharmaceutical Co., Ltd. has been approved for the registration of "Alpha-Lipoic Acid Tablets," which are primarily used for treating diabetic peripheral neuropathy [1] - The "Bisoprolol Amlodipine Tablets" are mainly used for the treatment of hypertension [1] - Obtaining these drug registration certificates will further enrich the company's product line and promote the upgrade of product capabilities [1]

Core Insights - Fuan Pharmaceutical's wholly-owned subsidiary, Yantai Zhichu Pharmaceutical Co., Ltd., has received a drug registration certificate for Alpha-Lipoic Acid Tablets from the National Medical Products Administration [1] - The drug is classified as a Class 3 chemical drug and is available in specifications of 0.2g and 0.6g [1] - The indication for Alpha-Lipoic Acid Tablets is for the treatment of sensory abnormalities caused by diabetic peripheral neuropathy [1] - A total of four companies, including Zhichu Pharmaceutical, have either passed or are deemed to have passed the consistency evaluation for this drug [1]